Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription 20.07.2026 1 Am J Clin Pathol 3 Am J Respir Crit Care Med 2 Ann Surg Oncol 4 BMC Cancer 2 Cancer Cell 1 Cancer Lett 1 Chest 5 Clin Cancer Res 1 Clin Lung Cancer 2 Eur J Cancer 1 Int J Cancer 1 Int J Oncol 1 Int J Radiat Oncol Biol Phys 1 J Cancer Res Clin Oncol 1 J Clin Oncol 2 J Comput Assist Tomogr 4 J Thorac Oncol 1 JAMA Oncol 13 Lung Cancer 1 Mol Carcinog 1 Nat Genet 1 Oncogene 1 Oncologist 3 PLoS One 2 Science 2 Thorax

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Pathol

1. SAVALOJA PINEAULT L, Martin N, Kelly MA, Temple-Smolkin RL, et al
   Standardized protocols for reflexing to a multigene panel for patients with non-small cell lung cancer: prevalence and perceived barriers to comprehensive, pathologist-ordered biomarker reflex testing.
   Am J Clin Pathol. 2026;166:aqag077.
   PubMed         Abstract available
   
   

   
   Am J Respir Crit Care Med

2. SHIJUBO N, Sumi T, Sugita S, Arioka K, et al
   Cryobiopsy Reveals the Architectural Maturity of Tertiary Lymphoid Structures in Lung Cancer.
   Am J Respir Crit Care Med. 2026 Jul 11:aamag367. doi: 10.1093.
   PubMed        
   
   
3. XIE N, Zhao M, Chen F, Zhao Y, et al
   Reply to Wang et al.: Potential biases in trans-omics gene-smoking interaction analyses of lung cancer.
   Am J Respir Crit Care Med. 2026 Jul 10:aamag361. doi: 10.1093.
   PubMed        
   
   
4. WANG K, Fu S, Xiang P, Xie L, et al
   Potential biases in trans-omics gene-smoking interaction analyses of lung cancer.
   Am J Respir Crit Care Med. 2026 Jul 10:aamag360. doi: 10.1093.
   PubMed        
   
   

   
   Ann Surg Oncol

5. TANG WF, Huang SQ, Li HJ, Tang X, et al
   Pathological Response, Tumor Microenvironment Dynamics, and Survival Dissociation after Neoadjuvant Chemoimmunotherapy for Lung Cancer with Rare Histological Subtypes.
   Ann Surg Oncol. 2026 Jul 15. doi: 10.1245/s10434-026-20028.
   PubMed         Abstract available
   
   
6. RAHOUMA M
   TRIM3 and the Ubiquitin Checkpoint: Reframing PD-L1 Stability in Non-small Cell Lung Cancer.
   Ann Surg Oncol. 2026 Jul 12. doi: 10.1245/s10434-026-20069.
   PubMed        
   
   

   
   BMC Cancer

7. SOLIMAN SH, Atef MM
   Efficacy and safety of metronomic oral vinorelbine in elderly patients with locally advanced and metastatic non-small cell lung cancer.
   BMC Cancer. 2026 Jul 17. doi: 10.1186/s12885-026-16517.
   PubMed         Abstract available
   
   
8. CHEN S, Guo F, Zhu J, Lin J, et al
   Adjuvant chemotherapy with or without EGFR-TKIs for resected EGFR-mutated non-small cell lung cancer: a pooled analysis of four randomized controlled trials.
   BMC Cancer. 2026 Jul 15. doi: 10.1186/s12885-026-16514.
   PubMed         Abstract available
   
   
9. BAO X, Xie M, Lin X, Liu Y, et al
   The Ki-67 proliferation index in tertiary lymphoid structures as a predictor of survival outcomes in patients with resectable non-small cell lung cancer.
   BMC Cancer. 2026 Jul 15. doi: 10.1186/s12885-026-16525.
   PubMed         Abstract available
   
   
10. QI F, Chen Y, Han Y, Jiang P, et al
    EGFR-TKI monotherapy versus combination therapy as first-line treatment for EGFR-mutant NSCLC with brain metastases: a real-world comparison analysis.
    BMC Cancer. 2026 May 20. doi: 10.1186/s12885-026-16193.
    PubMed         Abstract available
    
    

    
    Cancer Cell

11. IZUMI M, Kobayashi SS, Halmos B
    Targeting drug-tolerant persister cells: Let's bring on the TROPs!
    Cancer Cell. 2026;44:1333-1335.
    PubMed         Abstract available
    
    
12. LIU V, Sandor K, Yan PK, Miao Z, et al
    Clonal lineage tracing of innate immune cells in human cancer.
    Cancer Cell. 2026;44:1509-1521.
    PubMed         Abstract available
    
    

    
    Cancer Lett

13. GUMEROV R, He W, Luong P, Dall'Olio F, et al
    RNA-seq-based copy number inference for retrospective genomic characterization of lung cancer transcriptomes.
    Cancer Lett. 2026 Jul 17:218741. doi: 10.1016/j.canlet.2026.218741.
    PubMed        
    
    

    
    Chest

14. LLOYD SJ, Mortman MF, Monahan PO, Slaven JE, et al
    Evolving Lung Cancer Navigator Practice Through Targeted Professional Development: A Long-term Outcomes Analysis.
    Chest. 2026 Jul 16:S0012-3692(26)05973-8. doi: 10.1016/j.chest.2026.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

15. DI FEDERICO A, Pecci F, Jeng M, Peroni M, et al
    Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.
    Clin Cancer Res. 2026 Jul 14. doi: 10.1158/1078-0432.CCR-26-0924.
    PubMed         Abstract available
    
    
16. CIPRIANI L, Mascolo D, Scalera S, Bon G, et al
    Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.
    Clin Cancer Res. 2026 Jul 15. doi: 10.1158/1078-0432.CCR-26-1466.
    PubMed         Abstract available
    
    
17. DALL'OLIO FG, Zrafi W, Vasseur D, Garcia C, et al
    Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung Cancer.
    Clin Cancer Res. 2026 Jul 13. doi: 10.1158/1078-0432.CCR-25-3917.
    PubMed         Abstract available
    
    
18. CHEN M, Li R, Cheng Z, Wei Y, et al
    Divergent Tumor Immune Microenvironment and Response to Neoadjuvant Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer: A Single-Arm Phase II Trial.
    Clin Cancer Res. 2026 Jul 13. doi: 10.1158/1078-0432.CCR-25-4222.
    PubMed         Abstract available
    
    
19. GOLDBERG SB, Ahn MJ, Baik C, De Castro Carpeno J, et al
    Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.
    Clin Cancer Res. 2026 Jul 13. doi: 10.1158/1078-0432.CCR-26-0704.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

20. DIMITRIOU K, Shi S, Marginenau A, Blasi M, et al
    Chemoimmunotherapy Versus Chemotherapy for Extensive-Stage Small Cell Lung Cancer in the Real-World Setting: Retrospective Study of 904 Patients.
    Clin Lung Cancer. 2026;27:5-12.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

21. TANCREDI S, Cullati S, van der Linden BWA, Braggion A, et al
    Assessing the magnitude of surveillance bias in prostate cancer, melanoma and lung cancer.
    Eur J Cancer. 2026;245:116942.
    PubMed         Abstract available
    
    
22. SHAH R, Pathak GP, Fris J, Castonguay M, et al
    Coexisting driver alterations in non-small cell lung cancer: Prevalence, clonal architecture, and impact on survival and progression.
    Eur J Cancer. 2026;245:116936.
    PubMed         Abstract available
    
    

    
    Int J Cancer

23. XIONG Y, Guo W, Ma C, Ren X, et al
    Survival Outcomes Associated With Short-Acting Versus Long-Acting G-CSF Use During First-Line Chemoimmunotherapy for Advanced Lung Cancer: A Retrospective Study.
    Int J Cancer. 2026 Jul 16. doi: 10.1002/ijc.70644.
    PubMed         Abstract available
    
    

    
    Int J Oncol

24. XU Y, Duan H, Lu P, Liu F, et al
    The neural stem cell?NSCLC axis: Molecular drivers, microenvironment crosstalk and emerging therapies (Review).
    Int J Oncol. 2026;69:102.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

25. VAN ROSSUM PSN, Damen PJJ, Cortiula F, Hobbs BP, et al
    Pretreatment Risk Model for Radiation-Induced Lymphopenia Is Associated With Adjuvant Durvalumab Efficacy in Patients With Unresectable Stage III NSCLC.
    Int J Radiat Oncol Biol Phys. 2026;125:1434-1444.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

26. LEE JY, Chung CL, Tseng TT, Kuo SH, et al
    Effects of CDDO?TFEA on non?small cell lung cancer growth, apoptosis, and stemness via the MEK/ERK pathway.
    J Cancer Res Clin Oncol. 2026 Jul 15. doi: 10.1007/s00432-026-06544.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

27. RIMNER A, Lebow ES, Fitzgerald KJ, Kratochvil L, et al
    Durvalumab With Radiation Therapy in Patients With Inoperable Locally Advanced Non-Small Cell Lung Cancer Ineligible for Concurrent Chemoradiotherapy (DART).
    J Clin Oncol. 2026 Jul 16:JCO2502517. doi: 10.1200/JCO-25-02517.
    PubMed         Abstract available
    
    

    
    J Comput Assist Tomogr

28. HAMMER MM, Madan R
    MRI Evaluation of Indeterminate Pulmonary Nodules.
    J Comput Assist Tomogr. 2026;50:650-655.
    PubMed         Abstract available
    
    
29. NI X, Bao Y, Zhou C, Ni J, et al
    Radiomics Based on Dual-Layer Detector Spectral Computed Tomography for Predicting Histologic Subtypes and Ki-67 Expression in Non-Small Cell Lung Cancer.
    J Comput Assist Tomogr. 2026 Jul 8. doi: 10.1097/RCT.0000000000001894.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

30. CUI Q, Zhang JT, Yin H, Zhang KP, et al
    Comparison of circulating tumor DNA assays for molecular residual disease detection in non-small cell lung cancer.
    J Thorac Oncol. 2026 Jul 14:104090. doi: 10.1016/j.jtho.2026.104090.
    PubMed         Abstract available
    
    
31. SOCINSKI MA, Reck M, Paz-Ares L, Nishio M, et al
    AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 >/=50.
    J Thorac Oncol. 2026 Jul 14:104089. doi: 10.1016/j.jtho.2026.104089.
    PubMed         Abstract available
    
    
32. CUI C, Lin S, Waliany S, Lomibao M, et al
    Brief Report: First-line Chemoimmunotherapy and Chemotherapy Outcomes in Patients with RET Fusion-Positive Lung Cancer in LIBRETTO-431.
    J Thorac Oncol. 2026 Jul 10:104086. doi: 10.1016/j.jtho.2026.104086.
    PubMed         Abstract available
    
    
33. RAMALINGAM SS, Velcheti V, Altan M, de Castro G Jr, et al
    Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L).
    J Thorac Oncol. 2026 Jul 10:104087. doi: 10.1016/j.jtho.2026.104087.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

34. DI FEDERICO A, Compagno S, Mantuano F, Stumpo S, et al
    PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis.
    JAMA Oncol. 2026;12:753-761.
    PubMed         Abstract available
    
    

    
    Lung Cancer

35. NAKAYAMA M, Takasaki T, Yanagita M, Suzuki T, et al
    Negative-pressure pumping fluid as a cytological specimen for bronchoscopic diagnosis and molecular testing in lung cancer.
    Lung Cancer. 2026;219:109537.
    PubMed         Abstract available
    
    
36. MAYA R, Liora V, Dorith S, Amir O, et al
    Feasibility assessment of implementing lung cancer screening among current and former heavy smokers: a national pilot program in Israel (2021-2024).
    Lung Cancer. 2026;219:109536.
    PubMed         Abstract available
    
    
37. TOPKAN E, Selek M, Selek U
    Cannabis use disorder and lung cancer risk: Methodological considerations in interpretation.
    Lung Cancer. 2026;218:109497.
    PubMed        
    
    
38. CITARELLA F, Ferrara R, Di Maio M, Crucitti P, et al
    Germline testing in lung cancer: evidence of enrichment without a standardized selection strategy - a systematic review.
    Lung Cancer. 2026;219:109534.
    PubMed         Abstract available
    
    
39. HVIID C, Melchior LC, Berger SMS, Lofgren JO, et al
    Clonal divergence with acquired BRAF V600E in NSCLC with compound EGFR G719X/S768I after prolonged EGFR-TKI therapy.
    Lung Cancer. 2026;218:109517.
    PubMed         Abstract available
    
    
40. KALLA C, Monch D, Steinlein S, Pastore A, et al
    Genome-wide copy number analysis identifies AKT as a novel therapeutic target in pleural mesothelioma.
    Lung Cancer. 2026;218:109512.
    PubMed         Abstract available
    
    
41. ITCHINS M, Alexander M, Kao S, Nagrial A, et al
    Real-world treatment sequencing and survival in ROS1-Rearranged NSCLC across evolving treatment eras: Findings from the AURORA multi-centre registry (AURORA-ROS1).
    Lung Cancer. 2026;218:109500.
    PubMed         Abstract available
    
    
42. STEINESTEL K, Lower-Kiem LM, Ambrosi F, Becker AS, et al
    Limited predictive value of PD-L1 TPS for pathological response in NSCLC is not attributable to interobserver variability.
    Lung Cancer. 2026;218:109510.
    PubMed         Abstract available
    
    
43. OKAMOTO I, Cho BC, Goldberg SB, Goldman JW, et al
    Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD.
    Lung Cancer. 2026;218:109501.
    PubMed         Abstract available
    
    
44. MARTINOT T, Schonewille LHN, Ruano D, Steeghs EMP, et al
    Enrichment of SMARCA4 mutations in lung carcinomas presenting as cancer of unknown primary.
    Lung Cancer. 2026;218:109502.
    PubMed         Abstract available
    
    
45. LEE M, Yokomizo M, Salehi-Rad R, Billatos E, et al
    Characterization of the cancer-associated field of injury in the nasal epithelium in never-smokers.
    Lung Cancer. 2026;218:109506.
    PubMed         Abstract available
    
    
46. KATO T, Dong X, Takahashi T, Soparattanapaisarn N, et al
    Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study.
    Lung Cancer. 2026;218:109486.
    PubMed         Abstract available
    
    
47. MCNIERNEY D, Messick C, Reeve M, Chen J, et al
    Comparative performance of shape-sensing robotic-assisted bronchoscopy and CT-guided transthoracic biopsy in diagnosing peripheral pulmonary lesions.
    Lung Cancer. 2026;218:109487.
    PubMed         Abstract available
    
    

    
    Mol Carcinog

48. LIANG X, Nakhi A, Dosa PI, Georg GI, et al
    LKB1 Loss Sensitizes Lung Tumor Spheres to Mitomet-Induced Ferroptosis, and These Effects are Enhanced by mTOR Inhibition.
    Mol Carcinog. 2026;65:963-976.
    PubMed         Abstract available
    
    

    
    Nat Genet

49. WALTER DM, Cho K, Sivakumar S, Denney D, et al
    U2AF1 mutations rescue deleterious exon skipping induced by KRAS mutations.
    Nat Genet. 2026;58:1661-1671.
    PubMed         Abstract available
    
    

    
    Oncogene

50. CHEN Y, Yan H, Zhang Y, Lv Q, et al
    MTAP deficiency enhances collective metastasis in non-small cell lung cancer via WNT3A methylation.
    Oncogene. 2026 Jul 10. doi: 10.1038/s41388-026-03886.
    PubMed         Abstract available
    
    

    
    Oncologist

51. GHEEYA JS, Singh R, Li M, Ahmadian S, et al
    Methylation-based Liquid Biopsy Facilitates Early Detection of Small Cell Transformation in ALK-rearranged Non-Small Cell Lung Cancer.
    Oncologist. 2026 Jul 14:oyag271. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    PLoS One

52. CHEN F, Yan Y, Yang W, Li Z, et al
    Characterization of a novel lncRNA RP3-340N1.2 and its association with a miR-4650-5p/SHC1-related regulatory network in lung adenocarcinoma.
    PLoS One. 2026;21:e0353744.
    PubMed         Abstract available
    
    
53. SUFYAN M, Qian J, Li J, Imran A, et al
    Adaptive geometric-attention network for two-stage lung nodule segmentation and malignancy classification in federated healthcare IoT edge environments.
    PLoS One. 2026;21:e0341096.
    PubMed         Abstract available
    
    
54. ALAHDAL MA, Alahdal H, Binothman N, Aljadani M, et al
    Heptapharmacological activity of Quercetin-3-O-phosphate against lung cancer pathways.
    PLoS One. 2026;21:e0349042.
    PubMed         Abstract available
    
    

    
    Science

55. DECKER WK
    Lymph nodes now optional.
    Science. 2026;393:242-243.
    PubMed         Abstract available
    
    
56. MATTIUZ R, Boumelha J, Aerakis E, Le Berichel J, et al
    Dendritic cells control tertiary lymphoid structure development and maintenance in cancer.
    Science. 2026;393:eady1678.
    PubMed         Abstract available
    
    

    
    Thorax

57. BLANQUART C, Scherpereel A
    Optimising response to immunotherapies in pleural mesothelioma: clinical data and alternative models for the evaluation of new strategies.
    Thorax. 2026;81:806-817.
    PubMed         Abstract available
    
    
58. ARNOULD M, Neilly MDJ, Blyth KG, Jean D, et al
    Intratumour, anatomical and temporal heterogeneity in mesothelioma.
    Thorax. 2026;81:796-805.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum